Is hsa‐miR‐21‐5p a potential biomarker of vulnerable atherosclerotic plaque?

• DOI: 10.1096/fasebj.2019.33.1_supplement.522.3
• Publication Date: 2021-06-22T00:42:54Z
• Authors: Michał Krzysztof ...; Wiktor Paskal; Agata Gondek; Grzegorz Opolski; Agnieszka Barbara...
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

INTRODUCTIONVulnerable atherosclerotic plaque localized in coronary arterial bed is clinically important, because its rupture leads to a thrombus generation, which can totally occlude the culprit coronary artery causing myocardial infarction. Therefore finding a biomarker characteristic for a vulnerable plaque is warranted. A potential candidate is hsa‐miR‐21‐5p, a microRNA particle which promotes atherosclerotic plaque destabilization by increasing MMP‐9 expression and by enhancing local inflammatory state (negative regulation of SMAD‐7 expression).AIM OF THE STUDYAssessment, whether hsa‐miR‐21‐5p serum level differs significantly in patients with unstable coronary artery disease comparing to patients with stable coronary disease and myocardial infarction.MATERIALS AND METHODSPatients (n=42) were divided into 5 groups – ST‐segment elevation myocardial infarction (STEMI) (n=8); non‐ST segment elevation myocardial infarction (NSTEMI) (n=10), unstable angina (n=8), stable coronary artery disease (sCAD) (n=8) and 8 healthy volunteers (W). Serum samples were taken and hsa‐miR‐21‐5p relative expression level (in reference to hsa‐miR‐191‐5p and hsa‐miR‐93‐3p) was measured in each sample by RT‐qPCR. Serum samples form STEMI, NSTEMI and UA groups were taken within 24 hours of admission, before coronary angiography procedure. The results were statistically assessed on STATISTICA 13 programme.RESULTSThe results have shown, that hsa‐miR‐21‐5p serum level differs significantly between STEMI and UA group (5,955 vs 2,311; p= 0,04). No significant differences occurred between UA and CAD groups (2,311 vs 1,990; p=0,66) and between CAD and healthy volunteers (1,99 vs 1,79; p = 0,77). Comparison between other groups (STEMI vs NSTEMI, NSTEMI vs UA) showed no statistically significant differences in hsa‐miR‐21‐5p relative expression level.CONCLUSIONSThe study has shown no evidence supporting the hypothesis, that hsa‐miR‐21‐5p is a biomarker of a vulnerable atherosclerotic plaque, because its expression level didn't vary significantly between UA and CAD group. However, a significant difference in hsa‐miR‐21‐5p serum level between STEMI and UA group was found. This correlation could indicate, that hsa‐miR‐21‐5p plays a role on initial stages of myocardial ischemia and infarction.Support or Funding InformationNone The relative expression level of hsa‐miR‐21‐5p between different study groups (STEMI vs UA; UA vs CAD; CAD vs W).imageThe relative expression level of hsa‐miR‐21‐5p between different study groups (STEMI vs UA; UA vs CAD; CAD vs W).This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.